Sun Pharma Inks Non-Exclusive License Agreement With Takeda To Introduce Vonoprazan Tablets In India

New Delhi: Sun Pharmaceutical Industries on Friday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise a novel gastrointestinal drug in India.

The company has entered into a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan tablets in strengths of 10 and 20 mg in India, the Mumbai-based drug major said in a statement.

Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.

“Sun Pharma is a leader in gastroenterology and we are excited to introduce Vonoprazan in India under non-exclusive patent license from Takeda,” Sun Pharma CEO – India Business Kirti Ganorkar said.

The partnership demonstrates the company’s commitment to gastrointestinal health by providing patients and healthcare practitioners with a novel treatment option to manage reflux esophagitis and other acid peptic disorders, he added.

Gastroesophageal Reflux Disease (GERD) is common in India.

In November 2023, Vonoprazan was approved by the US FDA for healing and maintenance of all grades of Erosive esophagitis and providing relief from heartburn associated with Erosive esophagitis, and in combination with amoxicillin and clarithromycin or amoxicillin alone for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Vonoprazan was discovered and developed by Takeda.

The drug is approved in India for treatment of adults with reflux esophagitis and other acid peptic disorders.

Related Posts

  • Pharma
  • July 10, 2025
  • 116 views
Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

  • Pharma
  • July 10, 2025
  • 101 views
Novartis wins approval for first malaria drug for newborns and babies

ZURICH: Novartis (NOVN.S), opens new tab said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Novartis wins approval for first malaria drug for newborns and babies

Novartis wins approval for first malaria drug for newborns and babies

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr